G

Genentech

Biotech firm creating medicines via R&D

Business Product Manager - Territory & Roster Management

Full-Time
$140.3k - $260.5k/yr+ Discretionary annual bonus
Senior
Bachelor's
South San Francisco, CA, USA
HybridHybrid schedule: 3 days per week on campus.
ProductProduct Management

About the job

Requirements
  • A bachelor's degree or equivalent combination of education and relevant professional experience in Business, Information Systems, Analytics, or a related field.
  • At least 5 years of product management expertise, including experience in a Product Manager or Product Owner role guiding an analytical or digital product through ideation, launch, scaling, and operations.
  • Prior experience in pharmaceutical, biotech, healthcare, or another highly regulated industry, leading enterprise life sciences CRM platforms and Territory Design, such as Veeva Vault CRM or Salesforce.
  • Experience developing and executing product enablement, training, communications, adoption, or organizational change programs.
  • Experience defining or measuring product adoption, user engagement, operational efficiency, and business-value key performance indicators.
  • Strong analytical and problem-solving skills, including the ability to translate user feedback, product data, and operational insights into actionable recommendations.
  • Understanding of application development methodologies, including Agile and Waterfall, functional requirements, process modeling and re-engineering, use case development, user acceptance testing, organizational change management, and large-scale system implementations.
  • Experience with Jira, Confluence, and other Agile tools.
Responsibilities
  • Partner with the CRM Suite Business Product Owner to define and execute the long-term vision, strategy, and roadmap for Territory and Roster Management products.
  • Lead the end-to-end strategy for product solutions that deliver a national- or team-level overview of talent placement and enable executive stakeholders to make data-driven strategic talent-flow and workforce-planning decisions.
  • Translate business needs into actionable technical requirements and collaborate with Technical Product Managers to evolve territory and roster management products continuously.
  • Prioritize new enhancements required to support downstream product needs.
  • Lead quarterly territory alignment and roster-member talent-flow health reviews with stakeholders.
  • Oversee territory alignment and roster management datasets, ensuring data quality, governance, and seamless upstream and downstream integrations.
  • Develop ad hoc reporting to support stakeholder decision-making.
  • Lead business process design and user acceptance testing to ensure high quality during feature rollouts.
  • Establish change management and enablement strategies to maximize user adoption and engagement across Commercial, Medical, and Government Affairs.
  • Drive cross-functional consensus and advocate for the product suite’s strategic value proposition to executive stakeholders.

About the company

Genentech conducts extensive biotechnology R&D to discover medicines and therapies for unmet medical needs. Its treatments, including biologics, are developed, approved, and marketed to patients through healthcare providers and systems. It differentiates itself by a large research footprint, a strong patent portfolio, and multiple FDA Breakthrough Therapy Designations that speed promising therapies to patients. The goal is to advance medical science and deliver high-quality, effective therapies while balancing access and affordability for patients and the medical community.

Company Size

10,001+

Company Stage

IPO

Headquarters

San Francisco, CA

Founded

1976

Get referred to Genentech

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Hillsboro broke ground September 28, 2026 on a $750 million device fill-finish plant.
  • The project adds 250 jobs and strengthens U.S. supply for oncology, neurology, immunology.
  • Roche opened Boston's CVRM Innovation Center on September 17, 2026, expanding discovery capacity.

What critics are saying

  • September 2026 layoffs cut 265 South San Francisco jobs, ending a 40-year plant.
  • June and July 2026 cuts removed 103 gRED roles, signaling continuing research retrenchment.
  • Vabysmo concentration leaves Genentech vulnerable to a retinal franchise reversal by 2027.

What makes Genentech unique

  • Roche-backed Genentech pairs drug discovery with manufacturing, diagnostics, and global commercialization at scale.
  • Vabysmo delivered real-world eye-disease data on September 30, 2026 across 28 countries.
  • The September 24, 2026 Earendil deal shows Genentech still commands elite biotech partners.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Performance Bonus
  • Relocation Assistance

Growth & Insights and Company News

6 month growth

0%

1 year growth

-3%

2 year growth

-3%
IndustryWeek
Oct 30th, 2026
Musk and milestones, Candy quiz and who's Breaking Ground: IndustryWeek's Weekly Review.

Musk and milestones, Candy quiz and who's Breaking Ground: IndustryWeek's Weekly Review. Also, let's talk interest rates, what's up in the Strait of Hormuz, the power of reverse innovation, and more. Oct. 30, 2026 Sit back and catch up with the latest IndustryWeek Weekly Review, where we share the top-performing content over the previous seven days. Here is our Top 10: Musk and Tesla Target a Big 2030 Milestone: The CEO of the automotive, energy and robotics manufacturer thinks vehicle production can be double the company's total capacity by 2030. Tesla's vehicle engineering VP says expansion investments are already starting to pay off. Halloween Quiz: Candy and Skelly and Pumpkins, Oh My! Your house may be covered in fake cobwebs and giant skeletons, but take this quiz to find out how much you know about where Halloween costumes and decorations come from. Sponsored recommendations. US Fed Holds Interest Rates Steady Despite Surging Inflation: U.S. President Donald Trump's war on Iran, launched in late February, has sent energy prices skyrocketing and fueled domestic inflation, alongside his wide-ranging tariff policies. 5 Manufacturers Breaking Ground on New US Facilities: Find out where companies like U.S. Steel, Genentech and Avio USA are investing in new facilities and expansion projects. Manufacturing Day 2026: Building a Strong Talent Pipeline in Florida: Gulf Coast manufacturer Merrick Industries collaborates with community partners every step of the way. Strait of Hormuz Watch: Escalating Tensions Constrain Shipping, Dim Prospects for Peace Talks: Data and insights tracking transit activity, oil prices, petroleum reserves, supply chain impacts and geopolitical developments affecting the waterway. Plan, Do, Check, Act (PDCA): Focus on the Learning: Why you should use Plan, Do, Check, Act as a learning cycle for solving problems, rather than as a checklist for implementing solutions. How Well Is Your Team Functioning? Take This Assessment and Find Out: Answering these nine questions will produce a reliable snapshot of your team's current effectiveness, and targeted suggestions for how to improve. The Power and Potential Trap of Reverse Innovation: Lessons from GE, Mercedes-Benz, Dewalt: Proper product differentiation ensures that new, higher value items are visually and materially distinct. Buyers of Metal Are Prioritizing Certainty Over Price. Which Means Metals CEOs Are Pushing Price: The leaders of Cleveland-Cliffs and Steel Dynamics have recently told investors that demand remains healthy while supplies are often limited. Expect prices to keep climbing into 2027. Voice your opinion! IndustryWeek quiz. Halloween Quiz: Candy and Skelly and Pumpkins, Oh My! Your house may be covered in fake cobwebs and giant skeletons, but take this quiz to find out how much you know about where Halloween costumes and decorations come from. TEST YOURSELF

Associated Press
Oct 16th, 2026
FDA approves Genentech's Enspryng as first at-home injection for thyroid eye disease

Genentech, a member of the Roche Group, said the US Food and Drug Administration (FDA) has approved Enspryng for adults with thyroid eye disease (TED). It is the first and only at-home subcutaneous treatment for the condition, and patients or caregivers can give it after training. In the Phase III SatraGO-2 trial, 52.9% of active TED patients on Enspryng had a proptosis response, against 23.4% on placebo. Diplopia fell in 60.7% versus 25.8%. The sister trial, SatraGO-1, missed its primary endpoint at week 24. No new safety signals emerged. The approval, which followed a priority review, is Enspryng's second indication after neuromyelitis optica spectrum disorder in 2020. The FDA is also reviewing it for MOGAD, with a decision expected in January 2027.

The Hindu BusinessLine
Oct 14th, 2026
Biocon inks global patent settlement pact with Genentech for breast cancer drug Pebrilzo.

Biocon inks global patent settlement pact with Genentech for breast cancer drug Pebrilzo. By PTI. Updated - October 14, 2026 at 02:43 PM. Biocon Ltd on Wednesday said it has entered into a global settlement and license agreement with Genentech for breast cancer drug Pebrilzo, its biosimilar to the reference product Perjeta (Pertuzumab). The patent settlement agreement resolves all pending disputes between the two companies across multiple jurisdictions, including the US and Canada, the biopharmaceutical company said in a regulatory filing on Wednesday. Under the terms of the agreement, Biocon is cleared to launch Pebrilzo in the European Union and the United Kingdom in the first quarter of calendar year (CY) 2027, followed by a launch in the US in the third quarter of CY 2028. For other rest of the world markets, the launch is slated for 2026-2028, or earlier under certain circumstances. THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS.

PR Newswire
Oct 13th, 2026
2026 Patient Innovators Awards winners announced at Courier Health's annual Summit.

2026 Patient Innovators Awards winners announced at Courier Health's annual Summit. Oct 13, 2026, 09:00 ET Honorees celebrated as biopharma gathered in New York City to chart the future of the patient experience NEW YORK, Oct. 13, 2026 /PRNewswire/ - Courier Health, the leading technology company for managing patient experiences, today announced the winners of the second annual Patient Innovators Awards, which recognize the biopharma teams and leaders going above and beyond to improve patient access, innovation, and overall outcomes. Winners were announced live on October 6th at the third annual Patient Innovators Summit in New York City. The invite-only event brought together Patient Services, Access & Reimbursement, and Commercial IT & Analytics leaders from more than 75 biopharma companies. Together, attendees represented more than 100 disease states and roughly 35 million patients with previously unmet needs. Four teams and one individual were recognized for driving innovation and measurably improving the patient experience: * Rare Disease Champions of the Year: KalVista, a Company of Chiesi Group * Patient Services Team of the Year: Priovant Therapeutics * Field Access Team of the Year: UCB, Inc. * Patient Champion of the Year: Rob Chuba, Alkermes * Patient Innovators of the Year: Bristol Myers Squibb's CAR T-cell therapy Patient Access Support Services (PASS) team "Being named Patient Services Team of the Year is a testament to the team and program we're building," said Lee Liberator, Vice President of Patient Services and Reimbursement at Priovant Therapeutics. "We've built a unique program centered around what patients actually need from us, and we're proud to be recognized for our commitment to innovating and championing a better patient experience." In his opening keynote, Danny Sigurdson, Founder and CEO of Courier Health, described the moment as a fork in the road. As manufacturers take greater internal control of their programs, data ownership, outcomes-based measurement, and AI-enabled workflow innovation have become critical. Organizations that invest in the right foundation will gain greater operational leverage to focus on their core competency - supporting patients and providers - while those that don't will fall further behind. "This year's Patient Innovators Awards winners are proof that a better path, and a brighter future, is already being built," said Danny Sigurdson. "These teams and our individual Patient Champion of the Year aren't afraid to challenge the status quo and rethink how their programs run. They never lose sight of the patient, and it's an honor to recognize their contributions." This year's Patient Innovators Summit featured 11 industry speakers from companies including Alkermes, Beren Therapeutics, Corcept Therapeutics, Compass Pathways, Dyne Therapeutics, Genentech, and Tarus Pharmaceuticals. The audience also heard a powerful firsthand story from Mark Dant, rare disease advocate and Volunteer Executive Director for the Ryan Foundation. About Courier Health Courier Health is a New York City-based technology company on a mission to improve the patient experience for hundreds of millions of people living with a chronic condition or rare disease. The company develops and delivers the fastest-growing patient experience solution for the life sciences industry. Companies that choose Courier Health are achieving double-digit improvements to patient starts, time-to-start and ongoing adherence to life-altering therapies. As host of the invite-only Patient Innovators Summit and publisher of The State of Patient-Centricity in Biopharma report, Courier Health is backed by leading investors, including Oak HC/FT, Norwest and Work-Bench. Follow Courier Health on LinkedIn and learn more at www.courierhealth.com. SOURCE Courier Health

Yahoo Finance
Oct 9th, 2026
FDA approves Tecentriq for stage III colon cancer, cutting recurrence risk by 50%

The FDA has approved Genentech's Tecentriq in combination with a fluoropyrimidine and oxaliplatin for adjuvant treatment of stage III deficient DNA mismatch repair colon cancer. This marks Tecentriq's twelfth indication in the US. The approval follows results from the Phase III ATOMIC study, published in The New England Journal of Medicine. The trial showed Tecentriq plus chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone. The 36-month disease-free survival was 86% with Tecentriq combined with mFOLFOX6, versus 76% with mFOLFOX6 alone. Nearly 25% of colon cancers are diagnosed at stage III. Almost one in three patients with stage III colon cancer experience recurrence within five years. This represents the first approved adjuvant immunotherapy regimen for this patient population.